KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 71 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96 | +1820.0% | 9,959 | +1860.4% | 0.00% | – |
| Q2 2023 | $5 | -94.0% | 508 | -95.2% | 0.00% | – |
| Q1 2023 | $83 | -26.5% | 10,608 | -36.8% | 0.00% | – |
| Q4 2022 | $113 | -100.0% | 16,787 | -0.2% | 0.00% | – |
| Q3 2022 | $244,000 | +47.9% | 16,819 | +0.4% | 0.00% | – |
| Q2 2022 | $165,000 | -33.5% | 16,755 | -0.3% | 0.00% | – |
| Q1 2022 | $248,000 | +47.6% | 16,810 | +32.7% | 0.00% | – |
| Q4 2021 | $168,000 | -51.7% | 12,663 | -36.5% | 0.00% | – |
| Q3 2021 | $348,000 | -64.7% | 19,947 | -51.5% | 0.00% | -100.0% |
| Q2 2021 | $985,000 | +13.9% | 41,096 | +22.1% | 0.00% | 0.0% |
| Q1 2021 | $865,000 | +279.4% | 33,659 | +180.5% | 0.00% | – |
| Q4 2020 | $228,000 | +51.0% | 12,000 | 0.0% | 0.00% | – |
| Q3 2020 | $151,000 | +4.1% | 12,000 | 0.0% | 0.00% | – |
| Q2 2020 | $145,000 | +57.6% | 12,000 | 0.0% | 0.00% | – |
| Q1 2020 | $92,000 | -57.0% | 12,000 | 0.0% | 0.00% | – |
| Q4 2019 | $214,000 | +54.0% | 12,000 | 0.0% | 0.00% | – |
| Q3 2019 | $139,000 | -47.7% | 12,000 | 0.0% | 0.00% | – |
| Q2 2019 | $266,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |